Home > Focus Areas > Breast Cancer Connect > Post
  • Saved

3yr
Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer - PubMed

Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35957949/

1 Ward of General Practice/International Medical Center, West China Hospital, Sichuan University, Chengdu, China. 2 Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, China. 3 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. 1 Ward of General Practice/International Medical Center, West China Hospital, Sichuan University, Chengdu, China.


Conclusion: Despite significant gains in PFS over AF, it is not a cost-effective treatment for HR , HER2− ABC in the USA at current drug prices.

  • 3yr
    In the text of the paper, the authors also looked at cost effectiveness of the abemaciclib/fulvestrant combination in Italy and Germany compared to placebo/fulvestrant, and they found that ICER was less than the willingness-to-pay threshold in Europe. What's the difference? drug prices in the U.S.